JP2018504911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504911A5 JP2018504911A5 JP2017540270A JP2017540270A JP2018504911A5 JP 2018504911 A5 JP2018504911 A5 JP 2018504911A5 JP 2017540270 A JP2017540270 A JP 2017540270A JP 2017540270 A JP2017540270 A JP 2017540270A JP 2018504911 A5 JP2018504911 A5 JP 2018504911A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- tnf
- amino acid
- acid sequence
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102100009534 TNF Human genes 0.000 claims 4
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 claims 3
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
Claims (1)
- TNFと結合できる腫瘍壊死因子受容体（TNFR）ポリペプチド又は当該ポリペプチドのTNF結合フラグメントであって、当該ポリペプチドが、配列番号:1のアミノ酸配列又は最適なアラインメント後に前記アミノ酸配列と少なくとも60%同一性を有するアミノ酸配列を含み、さらに当該ポリペプチド又はそのTNF結合フラグメントがN-末端VPAQVモチーフを含むが、ただし当該ポリペプチドはマウスTNFR p80ではないことを条件とする、前記ポリペプチド又はそのTNF結合フラグメント。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015900260 | 2015-01-29 | ||
| AU2015900260A AU2015900260A0 (en) | 2015-01-29 | Therapeutic and diagnostic agents | |
| PCT/AU2016/050052 WO2016119023A1 (en) | 2015-01-29 | 2016-01-29 | Therapeutic and diagnostic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018504911A JP2018504911A (ja) | 2018-02-22 |
| JP2018504911A5 true JP2018504911A5 (ja) | 2019-03-14 |
Family
ID=56542055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540270A Pending JP2018504911A (ja) | 2015-01-29 | 2016-01-29 | 治療及び診断剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180215805A1 (ja) |
| EP (1) | EP3250589A4 (ja) |
| JP (1) | JP2018504911A (ja) |
| AU (1) | AU2016212707A1 (ja) |
| CA (1) | CA2975017A1 (ja) |
| WO (1) | WO2016119023A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE055417T2 (hu) | 2016-12-09 | 2021-11-29 | Akston Biosciences Corp | Inzulin-Fc fúziók és alkalmazási eljárások |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| LT3892628T (lt) * | 2018-06-29 | 2022-12-12 | Akston Biosciences Corporation | Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| CA3159486A1 (en) | 2019-12-19 | 2021-06-24 | Thomas M. Lancaster | Ultra-long acting insulin-fc fusion proteins and methods of use |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| BR112022020486A2 (pt) | 2020-04-10 | 2023-01-17 | Akston Biosciences Corp | Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| CN111696624B (zh) * | 2020-06-08 | 2022-07-12 | 天津大学 | 基于自注意力机制的dna结合蛋白鉴定和功能注释的深度学习方法 |
| US11667689B2 (en) | 2021-07-23 | 2023-06-06 | Akston Biosciences Corporation | Insulin-Fc fusion proteins and methods of use to treat cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ629309A (en) * | 2012-02-22 | 2016-03-31 | Nvip Pty Ltd | Tumour necrosis factor receptor fusion proteins and methods of using the same |
-
2016
- 2016-01-29 US US15/546,889 patent/US20180215805A1/en not_active Abandoned
- 2016-01-29 CA CA2975017A patent/CA2975017A1/en not_active Abandoned
- 2016-01-29 JP JP2017540270A patent/JP2018504911A/ja active Pending
- 2016-01-29 EP EP16742590.9A patent/EP3250589A4/en not_active Withdrawn
- 2016-01-29 WO PCT/AU2016/050052 patent/WO2016119023A1/en active Application Filing
- 2016-01-29 AU AU2016212707A patent/AU2016212707A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504911A5 (ja) | ||
| JP2017048194A5 (ja) | ||
| JP2014193892A5 (ja) | ||
| NZ610075A (en) | Cxcr2 binding polypeptides | |
| JP2016527891A5 (ja) | ||
| RU2021134101A (ru) | Модифицированная j-цепь | |
| JP2015525217A5 (ja) | ||
| JP2016190847A5 (ja) | ||
| JP2016521688A5 (ja) | ||
| MX2017016105A (es) | Polinucleotidos y polipeptidos de adenovirus. | |
| JP2018504907A5 (ja) | ||
| JP2013509879A5 (ja) | ||
| JP2013172734A5 (ja) | ||
| JP2016509011A5 (ja) | ||
| JP2016532693A5 (ja) | ||
| SI3191511T1 (en) | Improved TNF binders | |
| JP2012532601A5 (ja) | ||
| JP2012082206A5 (ja) | ||
| JP2019514367A5 (ja) | ||
| JP2010088434A5 (ja) | ||
| NZ629309A (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| JP2015038108A5 (ja) | ||
| HRP20200511T1 (hr) | Cjepiva protiv bakterija chlamydia sp. | |
| JP2015524403A5 (ja) | ||
| WO2015107363A3 (en) | Mycobacterial antigen composition |